The 3rd PREDiCT:3D Models Summit (previously 3D Tissue Models) will continue to showcase disruptive preclinical strategies utilizing advanced in vitro models across target ID, compound discovery, safety assessment, ADMET studies and more.

Representing the continued investment of biopharma into the area, this year over 36 speakers from more than 30 pharma, academia, government and model development organizations have committed to present.

Serving up an unrivalled volume of content, PREDiCT: 3D Models Summit will drill into case studies across discovery and development areas to enable you to determine the practicality of 3D models in optimizing your therapeutic pipeline.